X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
EVX-101 is a novel, proprietary, gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), which is investigated for the treatment of major depressive disorder.
Lead Product(s): HSDB 4295,Carbidopa
Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
EVX-101 is a novel, proprietary, gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), which is investigated for the treatment of major depressive disorder.
Lead Product(s): HSDB 4295,Carbidopa
Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
EVX-101 is a proprietary, oral tablet, gastroretentive, slow-release formulation of 5-HTP and low-dose carbidopa. It is being developed for patients with depression responding inadequately to first-line SSRI/SNRI antidepressants monotherapy.
Lead Product(s): HSDB 4295,Carbidopa
Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
EVX-101 is a novel, proprietary gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), the natural precursor to serotonin, and low-dose carbidopa. It is being investegated for major depressive disorder.
Lead Product(s): HSDB 4295,Carbidopa
Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
EVX-101 is a novel, proprietary gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), the natural precursor to serotonin. It is under phase 1 clinical trials for the treatment of major depressive disorder.
Lead Product(s): HSDB 4295,Carbidopa
Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
